Affinage mechanistic annotation for APOC4 (human) Affinage Affinage (Claude Sonnet reading pass + Opus synthesis pass) 4 citations

Affinage mechanistic annotation for APOC4 (human)

Current model (mechanistic narrative)

APOC4 encodes a small apolipoprotein within the apolipoprotein E/C-I/C-II gene cluster, comprising 127 residues with a 25-residue signal peptide and two predicted amphipathic alpha-helical domains, expressed at low levels in human liver PMID:8530039. The amphipathic helical architecture is consistent with lipid association characteristic of exchangeable apolipoproteins, and genetic variation at the locus links apoC-IV to triglyceride metabolism [PMID:8530039, PMID:10996355]. Beyond this molecular characterization and its association with lipid traits, no enzymatic activity, receptor interaction, or reconstituted mechanism for apoC-IV has been characterized in the available corpus.

Affinage mechanism profile (Affinage's own GO/Reactome grounding)

Dated findings (citation-anchored)

Year Confidence Finding PMIDs Journal
1995 Medium APOC4 was identified as a new human gene within the apolipoprotein E/C-I/C-II gene locus. Nucleotide sequence analysis revealed a 3.3-kb gene with three exons and two introns. The predicted apoC-IV protein comprises 127 amino acid residues with a putative 25-residue signal peptide and two potential amphipathic alpha-helical domains. RNase protection analysis showed relatively low apoC-IV mRNA levels in human liver compared to apoC-II mRNA levels. PMID:8530039 Genomics
2000 Low Genetic variation in APOC4 (specifically Leu36Pro and Leu96Arg polymorphisms) was significantly associated with triglyceride levels in women, consistent with a role for apoC-IV in triglyceride metabolism. Three coding mutations predicting amino acid substitutions (Leu36Pro, Gly52Asp, Leu96Arg) were identified by SSCP and DNA sequencing. PMID:10996355 Atherosclerosis
2024 Low APOC4 protein was found to bind to hydroxyapatite (HAP) spherules within sub-retinal pigment epithelial deposits in age-related macular degeneration. Quantitative SWATH-MS proteomics showed significant differences in HAP-bound APOC4 levels between CFH risk-variant carriers and wild-type individuals, and immunofluorescence confirmed APOC4 presence at the RPE/choroid interface associated with sub-RPE spherules. PMID:29580721 Experimental eye research
2021 Low APOC4 was identified as a target gene of hsa-miR-372-3p in the NEAT1/hsa-miR-372-3p/AGPS/APOC4 axis involved in rapamycin-induced triglyceride accumulation. Bioinformatics and experimental analyses predicted APOC4 as a downstream target involved in TG metabolism dysregulation. PMID:33705959 Free radical biology & medicine

Citations